Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) [Phase 2]
This update reports results from the CheckMate 650 Phase 2 trial evaluating nivolumab plus ipilimumab, ipilimumab alone, and cabazitaxel in …
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus olaparib versus abiraterone acetate or enzalutamide in metastatic castration-resistant prostate …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) [Phase 2, Phase 3]
Phase II/Phase III clinical trial evaluating intravenous melphalan with autologous whole blood stem cell transplantation in castration-resis…
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 3]
Phase 3 clinical trial update comparing ipatasertib plus abiraterone plus prednisone/prednisolone vs placebo plus abiraterone plus prednison…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. [Phase 3]
A Phase 3 trial comparing docetaxel versus hormone therapy as second-line treatment for asymptomatic or oligosymptomatic metastatic castrati…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) [Phase 2]
A Phase 2 study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer has completed and results ha…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC [Phase 1, Phase 2]
An update on a Phase I dose-escalation study of fractionated 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Phase I Trial of 225Ac-J591 in Patients With mCRPC [Phase 1]
Phase I trial evaluating Actinium-225 labeled J591 (225Ac-J591) in metastatic castration-resistant prostate cancer has completed enrollment …
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway [Phase 2]
Phase 2 trial evaluating docetaxel and carboplatin in metastatic castration-resistant prostate cancer with BRCA1/2 pathway inactivation; stu…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating pembrolizumab and HER2Bi-armed activated T cells for metastatic castration-resistant prostate cancer has completed …
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating abiraterone acetate without exogenous glucocorticoids in men with castration-resistant prostate cancer; results com…
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients [Phase 3]
Phase 3 trial comparing ARB with Radium-223 versus ARB with placebo in metastatic castration-resistant prostate cancer was terminated; resul…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC [Phase 1, Phase 2]
Phase 1/2 trial evaluating LEE011 (ribociclib) in combination with docetaxel and prednisone for metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC [Phase 2]
Phase 2 study evaluating the addition of pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer; results have been p…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating enzalutamide with mifepristone in metastatic hormone-resistant prostate cancer completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment [Phase 2]
Phase 2 trial investigating CRLX101 in combination with enzalutamide for metastatic castration-resistant prostate cancer after prior enzalut…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer [Phase 2]
Open-label Phase II trial of AZD4635 in prostate cancer, including metastatic castration-resistant disease; trial completed with results pos…
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Navarixin in combination with pembrolizumab in adults with selected advanced/metastatic …
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency [Phase 2]
Phase 2 clinical trial update of rucaparib in patients with metastatic castration-resistant prostate cancer and homologous recombination gen…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 study of durvalumab and tremelimumab in chemotherapy-naive metastatic castration-resistant prostate cancer has completed; results we…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating the combination of testosterone and olaparib in castration-resistant prostate cancer has completed, with results …
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate [Phase 3]
Phase 3 trial update providing long-term safety follow-up and examining long-term exposure to abiraterone acetate in metastatic castration-r…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer [Phase 3]
This clinical trial update notes the completion of a Phase 3 study of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, wi…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 clinical trial evaluating sipuleucel-T in combination with stereotactic ablative body radiation (SABR) for metastatic castration-r…